Document Type : Letter to the Editor


Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran




  1. Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, et al. Natalizumab in multiple sclerosis: Long-term management. Int J Mol Sci 2017; 18(5): 940.
  2. Stosic M, De JP, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology 2011; 77(5): 505-7.
  3. Midaglia L, Rodriguez RM, Munoz-Garcia D. Severe haematological complications during treatment with natalizumab. Mult Scler 2012; 18(11): 1644-6.
  4. Cachia D, Izzy S, Berriosmorales I, Ionete C. Drug-induced thrombocytopenia secondary to natalizumab treatment. BMJ Case Rep 2014; 2014: bcr2013203313.
  5. Rini AM, Clerici VT, Rinaldi E, Modesto M, Pastore D, Confalonieri PA, et al. Severe thrombocytopenia during Natalizumab therapy: A case report. J Neurol Sci 2020; 409: 116587.